RLAY

Relay TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The post-earnings bull case is that May 5 preserved the constructive 2026 setup: cash runway now reaches into 2029, the May vascular-anomalies readout is near, ReDiscover-2 remains active, and management advanced the frontline triplet plan toward an early-2027 Phase 3 start.

Posture

Defensive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +1.7.

What can break

Checked sources did not surface a clear wave of post-earnings analyst target revisions, leaving external validation of the May 5 update limited.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $13.50 · Bull $17.00 · Bear $8.50

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $25.38

Why

Momentum97 · Δ7d +1.7

Value41 · Δ7d -0.1

Sentiment13 · Δ7d -1.2

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+1.7

Δ21d

+3.7

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-1.2

Δ21d

-6.0

Why this grade

Composite grade D. Momentum 97.0 / Value 41.1 / Sentiment 12.7

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$4.18B

Beta

1.60

Shares Out

217.94M

P/E (TTM) · Derived

-11.9

P/S (TTM)

163.03

P/FCF (TTM) · Derived

-15.64

Rev YoY

-60.9%

EPS YoY

-10.5%

Gross Margin

+73.3%

Op Margin

-3914.4%

Net Debt

-$522.06M

Current Ratio

22.13

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology